A
A H Steinhart
Researcher at University of Toronto
Publications - 20
Citations - 2934
A H Steinhart is an academic researcher from University of Toronto. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 14, co-authored 20 publications receiving 2796 citations. Previous affiliations of A H Steinhart include Mount Sinai Hospital, Toronto.
Papers
More filters
Journal ArticleDOI
Methotrexate for the Treatment of Crohn's Disease
Brian G. Feagan,J. Rochon,Richard N. Fedorak,E J Irvine,Gary Wild,Lloyd R. Sutherland,A H Steinhart,Gordon R. Greenberg,R Gillies,Marybeth Hopkins +9 more
TL;DR: In a group of patients with chronically active Crohn's disease, methotrexate was more effective than placebo in improving symptoms and reducing requirements for prednisone.
Journal ArticleDOI
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators.
Brian G. Feagan,Richard N. Fedorak,E J Irvine,Gary Wild,Lloyd R. Sutherland,A H Steinhart,Gordon R. Greenberg,John J. Koval,Cindy J. Wong,Marybeth Hopkins,Stephen B. Hanauer,John W.D. McDonald +11 more
TL;DR: In patients with Crohn's disease who enter remission after treatment with methotrexate, a low dose of methotRexate maintains remission.
Journal ArticleDOI
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
TL;DR: For patients with ulcerative colitis treated with inflIXimab, a detectable trough serum infliximab predicts clinical remission, endoscopic improvement and a lower risk for colectomy.
Journal ArticleDOI
Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial.
TL;DR: The objective of this study was to determine if butyrate given as enema therapy is effective in the treatment of active distal ulcerative colitis.
Journal ArticleDOI
Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy.
Dan Turner,Catharine M. Walsh,Eric I Benchimol,E. H. Mann,K E Thomas,C Chow,Robin McLernon,Thomas D. Walters,J Swales,A H Steinhart,Anne M. Griffiths +10 more
TL;DR: The Pediatric Ulcerative Colitis Activity Index (PUCAI), Travis and Lindgren’s indices strongly predicted non-response and should be used to screen for patients likely to fail corticosteroids and at day 5 to dictate the introduction of second-line therapies.